BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30711828)

  • 1. Assessment of iPSC teratogenicity throughout directed differentiation toward an alveolar-like phenotype.
    Mitchell A; Wanczyk H; Jensen T; Finck C
    Differentiation; 2019; 105():45-53. PubMed ID: 30711828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of high purity alveolar-like cells from iPSCs through depletion of uncommitted cells after AFE induction.
    Mitchell A; Drinnan CT; Jensen T; Finck C
    Differentiation; 2017; 96():62-69. PubMed ID: 28802115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratinocyte growth factor and dexamethasone plus elevated cAMP levels synergistically support pluripotent stem cell differentiation into alveolar epithelial type II cells.
    Schmeckebier S; Mauritz C; Katsirntaki K; Sgodda M; Puppe V; Duerr J; Schubert SC; Schmiedl A; Lin Q; Paleček J; Draeger G; Ochs M; Zenke M; Cantz T; Mall MA; Martin U
    Tissue Eng Part A; 2013 Apr; 19(7-8):938-51. PubMed ID: 23176317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human induced pluripotent stem cell-derived lung progenitor and alveolar epithelial cells attenuate hyperoxia-induced lung injury.
    Shafa M; Ionescu LI; Vadivel A; Collins JJP; Xu L; Zhong S; Kang M; de Caen G; Daneshmand M; Shi J; Fu KZ; Qi A; Wang Y; Ellis J; Stanford WL; Thébaud B
    Cytotherapy; 2018 Jan; 20(1):108-125. PubMed ID: 29056548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suspension culture improves iPSC expansion and pluripotency phenotype.
    Cuesta-Gomez N; Verhoeff K; Dadheech N; Dang T; Jasra IT; de Leon MB; Pawlick R; Marfil-Garza B; Anwar P; Razavy H; Zapata-Morin PA; Jickling G; Thiesen A; O'Gorman D; Kallos MS; Shapiro AMJ
    Stem Cell Res Ther; 2023 Jun; 14(1):154. PubMed ID: 37280707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration.
    El Khatib MM; Ohmine S; Jacobus EJ; Tonne JM; Morsy SG; Holditch SJ; Schreiber CA; Uetsuka K; Fusaki N; Wigle DA; Terzic A; Kudva YC; Ikeda Y
    Stem Cells Transl Med; 2016 May; 5(5):694-702. PubMed ID: 26987352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumourigenicity of iPS cells and their differentiated derivates.
    Liu Z; Tang Y; Lü S; Zhou J; Du Z; Duan C; Li Z; Wang C
    J Cell Mol Med; 2013 Jun; 17(6):782-91. PubMed ID: 23711115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo.
    Zhou Q; Ye X; Sun R; Matsumoto Y; Moriyama M; Asano Y; Ajioka Y; Saijo Y
    Stem Cells Transl Med; 2014 Jun; 3(6):675-85. PubMed ID: 24763685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of human foreskin fibroblast-derived induced pluripotent stem cells into hepatocyte-like cells.
    Wang J; Zhao P; Wan Z; Jin X; Cheng Y; Yan T; Qing S; Ding N; Xin S
    Cell Biochem Funct; 2016 Oct; 34(7):475-482. PubMed ID: 27569862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of Induced Pluripotent Stem Cells from Bovine Epithelial Cells and Partial Redirection Toward a Mammary Phenotype In Vitro.
    Cravero D; Martignani E; Miretti S; Accornero P; Pauciullo A; Sharma R; Donadeu FX; Baratta M
    Cell Reprogram; 2015 Jun; 17(3):211-20. PubMed ID: 26053520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives.
    Itakura G; Kawabata S; Ando M; Nishiyama Y; Sugai K; Ozaki M; Iida T; Ookubo T; Kojima K; Kashiwagi R; Yasutake K; Nakauchi H; Miyoshi H; Nagoshi N; Kohyama J; Iwanami A; Matsumoto M; Nakamura M; Okano H
    Stem Cell Reports; 2017 Mar; 8(3):673-684. PubMed ID: 28262544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Ethanol Extract of
    Kim A; Baek SJ; Shin S; Lee SY; Chung SK
    Nutrients; 2023 May; 15(10):. PubMed ID: 37242247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethanol extract of Magnoliae cortex (EEMC) limits teratoma formation of pluripotent stem cells by selective elimination of undifferentiated cells through the p53-dependent mitochondrial apoptotic pathway.
    Kim A; Lee SY; Seo CS; Chung SK
    Phytomedicine; 2020 Apr; 69():153198. PubMed ID: 32151917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct
    Xiang M; Lu M; Quan J; Xu M; Meng D; Cui A; Li N; Liu Y; Lu P; Kang X; Wang X; Sun N; Zhao M; Liang Q; Le L; Wang X; Zhang J; Chen S
    Theranostics; 2019; 9(1):290-310. PubMed ID: 30662568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of primordial germ cells from induced pluripotent stem cells of primary ovarian insufficiency.
    Leng L; Tan Y; Gong F; Hu L; Ouyang Q; Zhao Y; Lu G; Lin G
    Hum Reprod; 2015 Mar; 30(3):737-48. PubMed ID: 25586786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of human alveolar epithelial type I cells from pluripotent stem cells.
    Burgess CL; Huang J; Bawa PS; Alysandratos KD; Minakin K; Ayers LJ; Morley MP; Babu A; Villacorta-Martin C; Yampolskaya M; Hinds A; Thapa BR; Wang F; Matschulat A; Mehta P; Morrisey EE; Varelas X; Kotton DN
    Cell Stem Cell; 2024 May; 31(5):657-675.e8. PubMed ID: 38642558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts.
    Lu M; Peng L; Ming X; Wang X; Cui A; Li Y; Wang X; Meng D; Sun N; Xiang M; Chen S
    EBioMedicine; 2019 Apr; 42():443-457. PubMed ID: 30926422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient hematopoietic redifferentiation of induced pluripotent stem cells derived from primitive murine bone marrow cells.
    Pfaff N; Lachmann N; Kohlscheen S; Sgodda M; Araúzo-Bravo MJ; Greber B; Kues W; Glage S; Baum C; Niemann H; Schambach A; Cantz T; Moritz T
    Stem Cells Dev; 2012 Mar; 21(5):689-701. PubMed ID: 21732815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy.
    Sougawa N; Miyagawa S; Fukushima S; Kawamura A; Yokoyama J; Ito E; Harada A; Okimoto K; Mochizuki-Oda N; Saito A; Sawa Y
    Sci Rep; 2018 Feb; 8(1):3726. PubMed ID: 29487310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heightened potency of human pluripotent stem cell lines created by transient BMP4 exposure.
    Yang Y; Adachi K; Sheridan MA; Alexenko AP; Schust DJ; Schulz LC; Ezashi T; Roberts RM
    Proc Natl Acad Sci U S A; 2015 May; 112(18):E2337-46. PubMed ID: 25870291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.